Drug intelligence / Profile preview

eurestobart

Development stage: Phase 1
Lead developer: Elpiscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ES002023 (eurestobart) is a recombinant humanized IgG1 monoclonal antibody that specifically targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, also known as CD39). By inhibiting CD39, the drug aims to block the immunosuppressive adenosine pathway in the tumor microenvironment, thereby enhancing anti-tumor immune responses. It is being developed primarily for use in patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer and other malignancies. The drug is currently in phase 1 clinical trials. The developer of ES002023 is Elpiscience Biopharma[1][2][3][4][6][7].

Other names: eurestobart

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on eurestobart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eurestobart.

Explore the full profile